Latest & greatest articles for lisdexamfetamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lisdexamfetamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lisdexamfetamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lisdexamfetamine

1. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. (Abstract)

Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis. Psychostimulants are the first-line treatment in adults with attention-deficit hyperactivity disorder (ADHD). This meta-analysis aimed to evaluate the efficacy, acceptability, and tolerability of lisdexamfetamine (LDX), mixed amphetamine salts (MASs), modafinil (MDF

2020 The Annals of pharmacotherapy

2. Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V

Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lisdexamfetamindimesilat (Aufmerksamkeitsdefizit- Hyperaktivitätsstörung bei Erwachsenen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A19-40 Lisdexamfetamine dimesylate (attention deficit/hyperactivity disorder in adults) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-40 Version 1.0 Lisdexamfetamine dimesylate (ADHD in adults) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lisdexamfetamine dimesylate (attention deficit/hyperactivity

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Lisdexamfetamine

Lisdexamfetamine Top results for lisdexamfetamine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lisdexamfetamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

4. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. (Abstract)

Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. Prefrontal-limbic circuits that form the neural architecture for emotion to influence behavior have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and represent a potentially important target of medication treatment that has not been substantively evaluated. This study tested the effect of the psychostimulant prodrug lisdexamfetamine (...) dimesylate on amygdala activation and connectivity during the emotional bias of response execution and inhibition.Twenty-five adults with ADHD were scanned twice with event-related functional magnetic resonance imaging while performing an emotional go/no-go task after 3 to 4 weeks of lisdexamfetamine treatment and 3 weeks off medication in a randomized, counterbalanced, hybrid crossover design. Drug, trial type, and face emotion (happy, sad, or neutral) were included as within-subjects factors

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain

5. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. (Abstract)

Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. Psychostimulants have been used in the treatment of depression, with mixed results. This meta-analysis examines the efficacy and tolerability of the stimulant Lisdexamfetamine (LDX) as an add-on strategy in those with MDD who have failed to respond to an antidepressant.Randomized control trials were identified and extracted from Pubmed; Web of Science

2017 Journal of Affective Disorders

6. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. (Full text)

Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Preliminary placebo-controlled evidence paved the ground to the US Food and Drug Administration approval extension of lisdexamfetamine for the treatment of moderate-to-severe binge eating disorder (BED) in adults.To provide a preliminary qualitative and quantitative synthesis of the placebo (...) -controlled, randomized clinical trials (RCTs) considering the efficacy and tolerability of lisdexamfetamine in the acute and/or maintenance treatment of moderate-to-severe BED in adults.A preliminary, yet comprehensive, systematic review was performed by accessing a broad range of resources providing publicly available data about lisdexamfetamine at the time of inquiry (March 2016). Study eligibility criteria, participants, and interventions were considered focusing on major clinical and functional

2016 Neuropsychiatric disease and treatment PubMed abstract

7. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. (Abstract)

Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. An earlier meta-analysis of pediatric clinical trials indicated that lisdexamfetamine dimesylate (LDX) had a greater effect size than other stimulant medications. This work tested the hypothesis that the apparent increased efficacy was artifactual.The authors assessed two potential artifacts: an unusually high precision of measurement and an unusually low placebo effect. The authors evaluated

2015 Journal of attention disorders

8. Lisdexamfetamine dimesylate (Elvanse Adult®)

Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Lisdexamfetamine dimesylate (Elvanse Adult®) Penarth: All Wales Therapeutics and Toxicology (...) Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2534. 2015 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Attention Deficit Disorder with Hyperactivity

2015 Health Technology Assessment (HTA) Database.

9. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. (Full text)

Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. Several studies have shown that lisdexamfetamine (LDX) is efficacious in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).Aims of this study were to systematically review the efficacy, acceptability, and tolerability of LDX in child and adolescent ADHD. Any randomized controlled trials (RCTs) of LDX versus placebo

2015 Drug design, development and therapy PubMed abstract

10. Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis. (Abstract)

Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis. There are few approved therapies for adults with attention-deficit/hyperactivity disorder (ADHD) in Europe. Lisdexamfetamine (LDX) is an effective treatment for ADHD; however, no clinical trials examining the efficacy of LDX specifically in European adults have been conducted

2015 European psychiatry : the journal of the Association of European Psychiatrists

11. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. (Full text)

Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Recent studies have promised that lisdexamfetamine (LDX) is effective in the treatment of adults with attention-deficit hyperactivity disorder (ADHD).This systematic review was undertaken to summarize LDX efficacy, acceptability, and tolerability in adult ADHD. All randomized controlled trials (RCTs) of lisdexamfetamine compared with placebo were included for synthesis. Clinical trials published between January 1991 (...) , the response rate, and the remission rate. The overall discontinuation rate and the discontinuation rate due to adverse events were measured for acceptability and tolerability, respectively. A random effect model was applied for the synthesis of relative risks (RRs), and weighted mean differences or standardized mean differences (SMDs) with 95% confidence intervals (CIs).A total of 806 final study or safety participants were included. The dosage of lisdexamfetamine was 30 to 70 mg/day. The pooled mean

2014 Drug design, development and therapy PubMed abstract

12. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. (Abstract)

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Systematically review and synthesize the clinical evidence of treatments for attention deficit hyperactivity disorder (ADHD) by indirectly comparing established treatments in the UK with a drug recently approved in Europe (lisdexamfetamine [LDX]).children and adolescents.Europe. Comparators: methylphenidate (MPH), atomoxetine

2014 Current medical research and opinion

13. Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment) Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V. [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 186. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Attention Deficit Disorder

2014 Health Technology Assessment (HTA) Database.

14. lisdexamfetamine dimesylate (Elvanse®)

lisdexamfetamine dimesylate (Elvanse®) lisdexamfetamine dimesylate (Elvanse®) lisdexamfetamine dimesylate (Elvanse®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). lisdexamfetamine dimesylate (Elvanse®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 188. 2013 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision

2014 Health Technology Assessment (HTA) Database.

15. A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. (Full text)

A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. Here we review the safety and tolerability profile of lisdexamfetamine dimesylate (LDX), the first long-acting prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD).A PubMed search was conducted for English-language articles published up to 16 September 2013 using the following search terms: (lisdexamfetamine OR lisdexamphetamine OR SPD489 OR Vyvanse OR Venvanse OR NRP104 NOT review [publication

2014 CNS drugs PubMed abstract

16. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate Attention deficit h Attention deficit hyper yperactivity disorder in activity disorder in children and y children and young people: lisde oung people: lisdexamfetamine xamfetamine dimesylate dimesylate Evidence summary Published: 7 May 2013 nice.org.uk/guidance/esnm19 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May (...) 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Limited evidence from 1 RCT suggests that lisdexamfetamine dimesylate produces clinically meaningful benefits in ADHD symptoms compared with placebo. The adverse effect profile appears similar to other stimulant drugs, although theoretical advantages in terms of improved adherence and reduced abuse potential require further

2013 National Institute for Health and Clinical Excellence - Advice

17. Lisdexamfetamine dimesylate - Benefit assessment according to § 35a Social Code Book V

Lisdexamfetamine dimesylate - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Lisdexamfetamindimesilat – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-24 Lisdexamfetamine (...) dimesylate – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-24 Version 1.0 Lisdexamfetamine dimesylate – Benefit assessment acc. to § 35a SGB V 29 August 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lisdexamfetamine dimesylate – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Lisdexamfetamine dimesylate - Attention deficit hyperactivity disorder

Lisdexamfetamine dimesylate - Attention deficit hyperactivity disorder Common Drug Review CEDAC Meeting – November 18, 2009 Page 1 of 5 Notice of CEDAC Final Recommendation – December 18, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION LISDEXAMFETAMINE DIMESYLATE (Vyvanse – Shire Canada Inc.) Indication: Attention Deficit Hyperactivity Disorder Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that lisdexamfetamine not be listed. Reason for the Recommendation (...) : There is insufficient evidence that lisdexamfetamine offers a therapeutic advantage compared with less expensive alternatives. Of Note: The Committee considered whether or not lisdexamfetamine has less abuse potential compared with other agents. Based on evidence from three abuse liability studies comparing lisdexamfetamine with placebo or short acting agents and also considering post-marketing sources that there was insufficient evidence to support that abuse potential is less with lisdexamfetamine compared

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review